| Product Unit Size | Cost | Quantity | Stock |
|---|
VX-950 is an antiviral, inhibiting the NS3/4A serine protease. VX-950 rapidly decreases viral load by several orders of magnitude, shown in vitro, in vivo, and in clinical trials. This compound is used as a treatment for hepatitis C genotype 1, resulting in a higher rate of sustained virologic response than traditional therapies such as pegylated interferon plus ribavirin.
| Cas No. | 402957-28-2 |
|---|---|
| Purity | ≥98% |
| Formula | C36H53N7O6 |
| Formula Wt. | 679.85 |
| IUPAC Name | (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide |
| Synonym | Telaprevir |
| Melting Point | 236.7°C |
| Solubility | DMSO 136 mg/mL (200.04 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 2012 Sep;34(9):1857-82. PMID: 22951253.
McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2012;362(14):1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406
Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2009;16(9):1115-21. PMID: 19275615.
Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006 Mar;6(1):3–16. PMID: 16787300.